Today and tomorrow EATG is attending the European HIV Vaccine Alliance (EHVA) consortium meeting in Barcelona. The EATG is one of the 39 partners of the consortium that aims to develop a Multidisciplinary Vaccine Platform (MVP) in the fields of prophylactic and therapeutic HIV vaccines.
EATG’s representative Giulio Maria Corbelli reports from the meeting:
The EHVA project includes a clinical trial for therapeutic vaccination to be used in combination with a broadly neutralising antibody or not. The trial is about to start at the end of summer in five European countries (UK and Switzerland first, then Italy, Spain and Belgium).
During the first day of the meeting EATG presented about the need to manage trial participants expectations; many people consider being cured from the HIV infection very important but this is unlikely to happen very soon. The trial will hopefully come out with important results that will help future research in this field but we are not there yet. On the other hand, those who will join this trial need to understand the complexity of procedures of this trial. A network of community representatives setup by EATG will be available for answering questions and addressing concerns.
For more information on the project you can visit www.ehv-a.eu